ILIlke G S de Lange

Ilke G S de Lange

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilke G S de Lange has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparing the Feasibility of In-Person and Online Preventive Cognitive Therapy for Major Depressive Disorder After Partial Response to Repetitive Transcranial Magnetic Stimulation: Protocol for a Pilot Randomized Controlled Trial

    by Ilke G S de Lange, Mariejean R C Albers, Karel W F Scheepstra, Claudi L Bockting, Laurien Aben

    Background: In recent years, repetitive transcranial magnetic stimulation (rTMS) has become a first-line recommendation in the Netherlands for individuals with major depressive disorder (MDD) who have not responded to a minimum of 2 prior treatments. Although rTMS can be effective, there is a significant risk of relapse after treatment. Currently, there are no standardized treatment options available after rTMS treatment completion aimed at preventing relapse. Preventive cognitive therapy (PCT) is a brief psychological intervention designed to prevent relapse in partially and fully remitted individuals with MDD. Objective: This study aims to establish the feasibility of 2 distinct forms of PCT (online and face-to-face) after intensive rTMS treatment for responding patients. Methods: Participants who demonstrate partial or full response to rTMS, defined as at least 25% reduction in symptoms, as quantified using the Inventory of Depressive Symptomatology–Self-Report (IDS-SR) or an IDS-SR score of 22 or lower will be included. Twenty participants will be randomly allocated to either face-to-face or online PCT, and treatment adherence will be compared between face-to-face and online treatment. The study will be deemed feasible if at least 75% of participants complete PCT during the grant duration of 1.5 years. For PCT, we aim to see which delivery format is the most feasible. Secondarily, changes in affective states, assessed through experience sampling data during PCT, will be studied to establish usefulness for a larger randomized controlled trial aimed at evaluating the effectiveness of PCT after rTMS. Finally, possible MDD relapse will be monitored throughout the intervention and follow-up periods. Results: This study was funded in November 2023 by the Netherlands Organisation for Health Research and Development. It was reviewed and approved according to the Medical Research Involving Human Subjects Act ( Wet Medisch-Wetenschappelijk Onderzoek met Mensen ) by the Medical Research Ethics Committee of Amsterdam University Medical Center on June 17, 2024. Data collection started in August 2024 and ended in April 2026, with an inclusion of 11 participants. As of June 2026, data analysis has not yet started. We expect data analysis and manuscript preparation of results to be completed in December 2026. Conclusions: If this pilot study shows preferred feasibility of a specific format of PCT (either online or face-to-face) following rTMS treatment for depression, a larger-scale randomized controlled clinical trial may be performed to study the effects of PCT on remission duration, relapse rates, and affective states in remitted individuals with MDD after rTMS treatment using this preferred delivery format. This pilot will provide insights into the feasibility of face-to-face or online PCT after successful rTMS treatment in depression.

  • Open Access

    Comparing in-person to online Preventive Cognitive Therapy (PCT) for major depressive disorder after repetitive transcranial magnetic stimulation (rTMS) response: Protocol of a Randomized Controlled Trial Pilot Study (Preprint)

    by Ilke G.S. de Lange, Mariejean R.C. Albers, Karel W.F. Scheepstra, Claudi L. Bockting, Laurien Aben

    BACKGROUND In recent years, repetitive Transcranial Magnetic Stimulation (rTMS) has become a first-line recommendation in the Netherlands for individuals with Major Depressive Disorder (MDD) who have not responded to a minimum of two prior treatments. Although rTMS can be effective, a significant risk of relapse exists after treatment. Currently, there are no standardized treatment options available post rTMS treatment completion aimed at preventing relapse. Preventive Cognitive Therapy (PCT) is a brief psychological intervention designed to prevent relapse in partially and fully remitted individuals of MDD. OBJECTIVE This study aims to establish feasibility of adding PCT after intensive rTMS treatment for responding patients. METHODS This pilot randomized controlled trial aims to investigate the feasibility of adding PCT following rTMS treatment for depression, either online or face-to-face. Participants who demonstrate partial or full response to rTMS, defined as at least 25% reduction in symptoms as quantified by the Inventory of Depressive Symptomatology - Self Rated (IDS-SR) or with IDS-SR score of 22 or lower will be included. Twenty participants will be randomly allocated to either face-to-face or online PCT treatment and treatment adherence between face to face or online treatment will be compared. Secondary, changes in affective states assessed through experience sampling data during PCT will be studied to establish usefulness for a larger RCT aimed on the effectiveness of PCT after rTMS. Lasty, possible relapse of MDD will be monitored throughout the intervention and follow-up period. RESULTS This study was reviewed and approved according to the Medical Research Involving Human Subjects Act (WMO; ‘Wet Medisch-Wetenschappelijk Onderzoek met Mensen’) by the Medical Research Ethics Committee of the Amsterdam UMC on 17th of June 2024 (trial register: NL85703.018.23). As of September 2025, participant recruitment has ended after 11 included participants. We expect data analysis and expected results to be published in fall 2026. CONCLUSIONS If this pilot study shows feasibility of adding PCT following rTMS treatment for depression either online of face-to-face, a larger-scale randomized controlled clinical trial may be performed to study the effects of PCT on remission durations, relapse rates and affective states in remitted MDD individuals after rTMS treatment. This pilot will provide insight into feasibility of face-to-face or online PCT treatment after successful rTMS treatment in depression. CLINICALTRIAL This trial has been registered in the Dutch national trial registry (Trial number: NL85703.018.23)

  • Open Access

    MIND-NL diet adherence moderates the relation of low-grade systemic inflammation with neuroinflammation and cognitive functioning: an exploratory cross-sectional study in older adults

    by Lianne B. Remie, Mark R. van Loenen, Mara P.H. van Trijp, Ilke G.S. de Lange, Yannick Vermeiren, Jurriaan J. Mes, Nicolaas A. Puts, Joukje M. Oosterman, Esther Aarts

    Background: Observational studies have linked high adherence to the “Mediterranean-Dietary Approaches to Stop Hypertension Intervention for Neurodegenerative Delay” (MIND) diet to improved cognitive functions in older adults. The underlying peripheral and central mechanisms of this association remain poorly understood, although multiple nutrients in the MIND diet are known for their anti-inflammatory effects. Therefore, we explored the cross-sectional relation between MIND diet adherence (Dutch version), systemic inflammation, neuroinflammation, and cognitive functioning in older adults. In addition, we examined the role of intestinal barrier permeability in MIND diet associations with (neuro)inflammation. Methods: We included 88 older adults (60-75 year) at risk of cognitive decline. MIND-NL diet adherence was assessed using a food frequency questionnaire. Systemic inflammation (C-reactive protein levels, white blood cell-counts and neutrophil-to-lymphocyte ratio) and intestinal barrier permeability (lipopolysaccharide-binding protein, zonulin, and lipopolysaccharide) markers were measured in blood. Neuroinflammation-associated metabolites (myo-inositol, choline and creatine) were measured in the dorsolateral prefrontal cortex with proton magnetic resonance spectroscopy ( 1 H-MRS). Cognitive functioning was assessed with a neuropsychological test battery. Results: Linear models showed that both MIND diet adherence and systemic inflammation did not predict neuroinflammation or cognition independently. However, MIND diet adherence significantly moderated the relation between systemic inflammation and neuroinflammation (β=-0.11, p =0.04) as well as between systemic inflammation and cognition (β=0.044, p =0.02). Specifically, in individuals with lower MIND diet adherence (identified as scores ≤7), systemic inflammation was positively related to neuroinflammation, and negatively to cognition. Similarly, MIND diet adherence significantly moderated the relation between intestinal barrier permeability and neuroinflammation (β=-0.17, p =0.05). Finally, within participants with lower MIND adherence (median split at ≤8.75), systemic inflammation mediated the relation between the intestinal barrier permeability and neuroinflammation (β=0.427 [0.072; 0.891], p =0.04). Conclusion: Our findings suggest that higher MIND diet adherence might protect against the detrimental effect of systemic inflammation on neuroinflammation and cognitive functioning. Moreover, we demonstrated that greater adherence to the MIND diet may specifically protect against the systemic inflammation-mediated relationship between intestinal barrier permeability and neuroinflammation. These findings should be confirmed in randomised controlled trials.